Pietro Gatti
Research Subjects
Pietro Gatti has a total of 482 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Giorgio
Liver Unit and Interventional Ultrasound Unit, Athena Clinical Institute, Piedimonte Matese (CE), Italy
10 shared publications - Domenico Sansonno
Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy
10 shared publications Valentina Giorgio
Fondazione Policlinico A. Gemelli IRCCS, Department of Woman and Child Health and Public Health, Roma, Italy
8 shared publications- Gianfranco Lauletta
Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro” Medical School, Bari, Italy
7 shared publications - Angelo Andriulli
Division of Gastroenterology, Casa Sollievo Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy
6 shared publications - Maria Rosa Valvano
Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy
6 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 1 May 2021
- Published by Elsevier in Journal of Hepatology
- Vol. 74 (5) , 1097-1108
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis
- 1 May 2021
- Published by Elsevier in Journal of Hepatology
- Vol. 74 (5) , 1097-1108
Top Cited PapersOpen AccessPREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis
- Open Access
- 3 January 2021
- Published by Springer Nature in Journal of Ultrasound
- Vol. 25 (1) , 129-131
Non-enhanced Magnetic Resonance Imaging Compared to Ultrasound as a Surveillance Tool for Hepatocellular Carcinoma. Not all that glitters is gold: the ultrasound hepatologist’s point of view
- 3 January 2021
- Published by Springer Nature in Journal of Ultrasound
- Vol. 25 (1) , 129-131
Open AccessNon-enhanced Magnetic Resonance Imaging Compared to Ultrasound as a Surveillance Tool for Hepatocellular Carcinoma. Not all that glitters is gold: the ultrasound hepatologist’s point of view
- 1 August 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 296 (2) , E121-E122
CEUS LI-RADS Categories to Distinguish Hepatocellular Carcinoma and Non–Hepatocellular Carcinoma Malignancies
- 1 August 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 296 (2) , E121-E122
CEUS LI-RADS Categories to Distinguish Hepatocellular Carcinoma and Non–Hepatocellular Carcinoma Malignancies
- Open Access
- 1 February 2020
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 9 (1) , 62-64
Editorial on “Role of thermal ablation in the management of colorectal liver metastasis”
Editorial on “Role of thermal ablation in the management of colorectal liver metastasis”
- 1 February 2020
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 9 (1) , 62-64
Open AccessEditorial on “Role of thermal ablation in the management of colorectal liver metastasis”
Editorial on “Role of thermal ablation in the management of colorectal liver metastasis”
- Open Access
- 28 September 2019
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 7 (X) , 1-6
Intrahepatic Cholangiocarcinoma and Thermal Ablation: Long-term Results of An Italian Retrospective Multicenter Study
Background and Aims: Despite resection being considered the treatment of choice for intrahepatic cholangiocarcinoma (ICC), percutaneous thermal ablation can be an alternative treatment for patients unfit for surgery. Our aim was to compare long-term results of percutaneous sonographically-guided radiofrequency ablation (RFA) with high-powered microwave ablation (MWSA) in treatment of ICC. Methods: Results of 71 ICC patients with 98 nodules treated with RFA (36 patients) or MWSA (35 patients) between January 2008 and June 2018 in 5 Interventional Ultrasound centers of Southern Italy were retrospectively reviewed. Cumulative overall survival curves were calculated with the Kaplan-Meyer method and differences with the log-rank test. Eleven possible factors affecting survival were analyzed. Results: Overall survival of the entire series was 88%, 65%, 45% and 34% at 12, 36, 60 and 80 months, respectively. Patients treated with MWSA survived longer than patients treated with RFA (p < 0.005). The MWSA group with ICC nodules ≤3 cm or nodules up to 4 cm survived longer than the RFA group (p < 0.0005). In patients with nodules >4 cm, no significant difference was found. Disease-free survival and progression-free survival were better in the MWSA group compared to the RFA group (p < 0.005). Diameter of nodules and MWSA were independent factors predicting a better survival. No major complications were observed. Conclusions: MWSA is superior to RFA in treating ICC unfit for surgery, achieving better long-term survival in small (≤3 cm) ICC nodules as well as nodules up to 4 cm of neoplastic tumors and should replace RFA.
- 28 September 2019
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 7 (X) , 1-6
Open AccessIntrahepatic Cholangiocarcinoma and Thermal Ablation: Long-term Results of An Italian Retrospective Multicenter Study
Background and Aims: Despite resection being considered the treatment of choice for intrahepatic cholangiocarcinoma (ICC), percutaneous thermal ablation can be an alternative treatment for patients unfit for surgery. Our aim was to compare long-term results of percutaneous sonographically-guided radiofrequency ablation (RFA) with high-powered microwave ablation (MWSA) in treatment of ICC. Methods: Results of 71 ICC patients with 98 nodules treated with RFA (36 patients) or MWSA (35 patients) between January 2008 and June 2018 in 5 Interventional Ultrasound centers of Southern Italy were retrospectively reviewed. Cumulative overall survival curves were calculated with the Kaplan-Meyer method and differences with the log-rank test. Eleven possible factors affecting survival were analyzed. Results: Overall survival of the entire series was 88%, 65%, 45% and 34% at 12, 36, 60 and 80 months, respectively. Patients treated with MWSA survived longer than patients treated with RFA (p < 0.005). The MWSA group with ICC nodules ≤3 cm or nodules up to 4 cm survived longer than the RFA group (p < 0.0005). In patients with nodules >4 cm, no significant difference was found. Disease-free survival and progression-free survival were better in the MWSA group compared to the RFA group (p < 0.005). Diameter of nodules and MWSA were independent factors predicting a better survival. No major complications were observed. Conclusions: MWSA is superior to RFA in treating ICC unfit for surgery, achieving better long-term survival in small (≤3 cm) ICC nodules as well as nodules up to 4 cm of neoplastic tumors and should replace RFA.
- 1 August 2019
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 9 (8) , 1466-1469
Can contrast-enhanced ultrasound with perfluorobutane add value in detection of hepatocellular carcinoma in cirrhosis during surveillance?
- 1 August 2019
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 9 (8) , 1466-1469
Can contrast-enhanced ultrasound with perfluorobutane add value in detection of hepatocellular carcinoma in cirrhosis during surveillance?
- 12 March 2019
- Published by Springer Nature in Journal of Ultrasound
- Vol. 22 (3) , 363-370
Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report
Purpose Hepatocellular carcinoma (HCC) is the most common form of liver cancer. In advanced cancer stages (metastatic disease and/or vascular invasion), the generally accepted standard of care is systemic therapy using sorafenib as first-line treatment and, recently, regorafenib and nivolumab as second-line treatment, but the quality of life and the prognosis of patients remain very poor. Our paper reports a case of US-guided radiofrequency ablation (RFA) of both intraparenchymal HCC and inferior vena cava tumor thrombus. Methods We treated a patient with HCC associated with tumor thrombus extending into vena cava after failure of sorafenib therapy using US-guided radiofrequency ablation (RFA). Results A good radiological and clinical response was observed in association with excellent tolerability. The patient has been followed up for 15 months from the ablation, is alive, and is in a good clinical condition without evidence of tumor recurrence. Conclusion This is the first case in which this minimally invasive percutaneous procedure has been successfully used to treat an HCC thrombus entering the vena cava.
- 12 March 2019
- Published by Springer Nature in Journal of Ultrasound
- Vol. 22 (3) , 363-370
Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report
Purpose Hepatocellular carcinoma (HCC) is the most common form of liver cancer. In advanced cancer stages (metastatic disease and/or vascular invasion), the generally accepted standard of care is systemic therapy using sorafenib as first-line treatment and, recently, regorafenib and nivolumab as second-line treatment, but the quality of life and the prognosis of patients remain very poor. Our paper reports a case of US-guided radiofrequency ablation (RFA) of both intraparenchymal HCC and inferior vena cava tumor thrombus. Methods We treated a patient with HCC associated with tumor thrombus extending into vena cava after failure of sorafenib therapy using US-guided radiofrequency ablation (RFA). Results A good radiological and clinical response was observed in association with excellent tolerability. The patient has been followed up for 15 months from the ablation, is alive, and is in a good clinical condition without evidence of tumor recurrence. Conclusion This is the first case in which this minimally invasive percutaneous procedure has been successfully used to treat an HCC thrombus entering the vena cava.
- 6 March 2019
- Published by Springer Nature in Journal of Ultrasound
- Vol. 22 (1) , 53-58
Ultrasound-guided percutaneous irreversible electroporation of hepatic and abdominal tumors not eligible for surgery or thermal ablation: a western report on safety and efficacy
Purpose To report our first results on sixteen patients affected by liver and abdominal malignant tumors, unfit for surgery or thermal ablation, treated with US-guided percutaneous irreversible electroporation (IRE). Methods From June 2014 to December 2016, all patients meeting the inclusion criteria (malignant hepatic or abdominal tumors not eligible for resection or thermal ablation) and not meeting the exclusion criteria (heart arrhythmia, pro-hemorrhagic hematological alterations, tumor size > 8 cm, presence of a biliary metallic stent) referred to our institutions were prospectively enrolled to undergo percutaneous US-guided irreversible electroporation (IRE). Sixteen patients (age range 59–68 years, mean 63; 7 females) with 18 tumors (diameter range 1.3–7.5 cm) fulfilled the inclusion criteria and were included in the study. Data concerning efficacy (tested by a 1-week CEUS and a 4-week enhanced CT and/or enhanced MRI) and safety were recorded during a 18-month follow up. Results All patients completed a 35–50-min procedure without complications. One patient with 6 cm Klatskin tumor also underwent a second session for 1 month. A 1-week CEUS and a 4-week e-CT and/or e-MRI arterial phase contrast enhancement analysis showed an overall reduction of arterial flow with confirmation of unenhanced lesions for seven nodules. After 1–18 months of follow up, no major complications were recorded and no tumor-related death occurred. The lesions of two patients disappeared 3 and 6 months after their treatment, respectively. Conclusions IRE is a promising ablation modality in the treatment of malignant hepatic and abdominal tumors unsuitable for resection or thermal ablation.
- 6 March 2019
- Published by Springer Nature in Journal of Ultrasound
- Vol. 22 (1) , 53-58
Ultrasound-guided percutaneous irreversible electroporation of hepatic and abdominal tumors not eligible for surgery or thermal ablation: a western report on safety and efficacy
Purpose To report our first results on sixteen patients affected by liver and abdominal malignant tumors, unfit for surgery or thermal ablation, treated with US-guided percutaneous irreversible electroporation (IRE). Methods From June 2014 to December 2016, all patients meeting the inclusion criteria (malignant hepatic or abdominal tumors not eligible for resection or thermal ablation) and not meeting the exclusion criteria (heart arrhythmia, pro-hemorrhagic hematological alterations, tumor size > 8 cm, presence of a biliary metallic stent) referred to our institutions were prospectively enrolled to undergo percutaneous US-guided irreversible electroporation (IRE). Sixteen patients (age range 59–68 years, mean 63; 7 females) with 18 tumors (diameter range 1.3–7.5 cm) fulfilled the inclusion criteria and were included in the study. Data concerning efficacy (tested by a 1-week CEUS and a 4-week enhanced CT and/or enhanced MRI) and safety were recorded during a 18-month follow up. Results All patients completed a 35–50-min procedure without complications. One patient with 6 cm Klatskin tumor also underwent a second session for 1 month. A 1-week CEUS and a 4-week e-CT and/or e-MRI arterial phase contrast enhancement analysis showed an overall reduction of arterial flow with confirmation of unenhanced lesions for seven nodules. After 1–18 months of follow up, no major complications were recorded and no tumor-related death occurred. The lesions of two patients disappeared 3 and 6 months after their treatment, respectively. Conclusions IRE is a promising ablation modality in the treatment of malignant hepatic and abdominal tumors unsuitable for resection or thermal ablation.
- Open Access
- 11 July 2018
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 6 (x) , 1-7
Microwave Ablation in Intermediate Hepatocellular Carcinoma in Cirrhosis: An Italian Multicenter Prospective Study
Background and Aims: To report long-term results in treatment of intermediate hepatocellular carcinoma (HCC) in cirrhotics using new high-powered microwaves (MWS) ablation alone.
- 11 July 2018
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 6 (x) , 1-7
Open AccessMicrowave Ablation in Intermediate Hepatocellular Carcinoma in Cirrhosis: An Italian Multicenter Prospective Study
Background and Aims: To report long-term results in treatment of intermediate hepatocellular carcinoma (HCC) in cirrhotics using new high-powered microwaves (MWS) ablation alone.
- 1 June 2018
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 7 (3) , 192-194
Ablative therapies for intrahepatic cholangiocarcinoma
Ablative therapies for intrahepatic cholangiocarcinoma
- 1 June 2018
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 7 (3) , 192-194
Ablative therapies for intrahepatic cholangiocarcinoma
Ablative therapies for intrahepatic cholangiocarcinoma